ABOUT THE EVENT
The global respiratory drug market is expected to continue to grow in the coming years due to several factors. While Covid-19 may not be the top concern anymore, rising air pollution levels, prevalence of respiratory diseases such as asthma, COPD, and cystic fibrosis, and an ageing population contribute to the increasing pervasiveness of respiratory diseases.
We come here, together to discuss the latest developments and breakthroughs in the field of respiratory medicine, and to explore new strategies for improving the health and quality of life of patients with respiratory diseases.
The goal of this summit is to provide a platform for experts in the field of respiratory medicine to share their insights and knowledge, and to collaborate on new ideas for improving the diagnosis, treatment, and management of respiratory diseases. Over the course of the conference, we will hear from leading researchers, scientists and industry professionals, who will share their expertise and experiences in the inhalation field.
Do not forget to mark 5-6 October 2023 in your calendar!
You will have the chance to meet and network with leading researchers, pharmaceutical industry professionals, and regulatory experts, allowing you to expand your professional network and gain new insights into the latest developments and trends.
CONFERENCE LEARNING POINTS
- Nasal and pulmonary drug delivery
- Expert talk on regulations in the EU
- Aerosol drug delivery
- Risk of nebulizer treatments
- Update on smart and mesh inhalers
- Current developments in digital health
- In vitro and In vivo analysis
- Combination inhalers
As a member of our team, you’ll help deliver on our mission to strive for better health and a brighter future for people worldwide through leading innovation in medicine. It’s a responsibility that motivates and inspires us all.
You’ll find your own professional inspiration at Takeda, in the area that suits your interests and skills. Whether that’s R&D, Oncology, Corporate, Manufacturing, Quality, or another business unit, wherever you find yourself at Takeda, you’ll enjoy a meaningful career that’s making a positive impact on patients, people and the planet.
– Bringing peace of mind to patients and loved ones by safely and rapidly delivering more medication to the lungs, increasing speed of recovery.
– Helping care providers more effectively treat patients, while also empowering them to focus on strategic tasks and reducing their risk of exposure to patient-generated infectious aerosols.
– Assisting health systems to improve patient satisfaction and outcomes, reduce admissions, increase hospital discharges and decrease length of stay by more safely and effectively getting medications to patients.
– Helping to drive the next generation of effective and safer aerosol medication delivery for the treatment of many of the world’s most difficult health issues, in partnership with pharmaceutical companies.
Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. More than 52,000 employees serve over 130 markets in the three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.
With unparalleled diagnostics and drug development capabilities, they accelerate innovation and provide insight to improve health and improve lives. Whether they’re a patient, provider, researcher or in the pharmaceutical industry, they’re here for you. More than 70,000 employees strong, they serve clients in more than 100 countries. Labcorp (NYSE: LH) reported revenue of $14 billion in FY 2020.
Leveraging the expertise of our unique multidisciplinary team and our state-of-the-art capabilities in modeling, material science, process design, quality assurance and control, we redefine current thinking in the field of healthcare offering cutting-edge, scientific solutions tailored to customer needs.
RCPE’s services encompass the entire value chain of pharmaceutical product development: continuous API synthesis, advanced formulations, next-generation manufacturing, and also device design and optimization.
As a non-profit, private company owned by Graz University of Technology (65%), University of Graz (20%) and Joanneum Research GmbH (15%), we link outstanding science, application and industry in a business-oriented approach.
RCSI’s main campus is situated on St. Stephen’s Green and York Street in central Dublin and incorporates schools of medicine, pharmacy, physiotherapy and nursing. It offers undergraduate and postgraduate education in a number of healthcare fields.
The RCSI achieved Ireland’s highest position in the Times Higher Education (THE) University Impact Rankings 2021, coming joint second in the world for ‘Good Health and Wellbeing’ from a total of 871 institutions. THE University Impact Rankings recognise universities around the world for their social and economic impact based on the United Nations’ 17 Sustainable Development Goals (SDGs).
We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Arterial Hypertension.
MEGGLE Business Unit Excipients serves the pharmaceutical and nutraceutical markets with a global network of offices and authorized distribution partners. Supporting supply chain security with manufacturing facilities in Europe and North America. Our broad portfolio of products, multiple manufacturing locations, technical centers in major markets, and innovative technologies, make MEGGLE the preferred supplier and valued partner for our customers.
• Lactose monohydrate
• Anhydrous Lactose
• Co-Processed Excipients
• Lactose for Inhalation
• Lactose for lyophilization and parenteral applications
• Tailor-made lactose products
• Spray drying
• Product Customization
The Company’s proprietary, propellant-free, purely mechanical device delivers medication to the lungs more effectively than other types of inhalers and is poised to change the treatment paradigm in large markets including asthma and COPD. Softhale’s products to be used for pharmaceutical development and approval processes are innovative as well as cost-optimized.